- Home
- CXAI vs CRIS Comparison
CXAI vs CRIS Comparison
Compare CXAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- CRIS
- Stock Information
- Founded
- CXAI N/A
- CRIS 2000
- Country
- CXAI United States
- CRIS United States
- Employees
- CXAI N/A
- CRIS N/A
- Industry
- CXAI EDP Services
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXAI Technology
- CRIS Health Care
- Exchange
- CXAI Nasdaq
- CRIS Nasdaq
- Market Cap
- CXAI 22.4M
- CRIS 21.3M
- IPO Year
- CXAI N/A
- CRIS 2000
- Fundamental
- Price
- CXAI $1.00
- CRIS $1.85
- Analyst Decision
- CXAI
- CRIS Strong Buy
- Analyst Count
- CXAI 0
- CRIS 2
- Target Price
- CXAI N/A
- CRIS $16.50
- AVG Volume (30 Days)
- CXAI 493.4K
- CRIS 153.9K
- Earning Date
- CXAI 08-11-2025
- CRIS 07-31-2025
- Dividend Yield
- CXAI N/A
- CRIS N/A
- EPS Growth
- CXAI N/A
- CRIS N/A
- EPS
- CXAI N/A
- CRIS N/A
- Revenue
- CXAI $6,548,000.00
- CRIS $11,202,000.00
- Revenue This Year
- CXAI N/A
- CRIS N/A
- Revenue Next Year
- CXAI $60.00
- CRIS $10.67
- P/E Ratio
- CXAI N/A
- CRIS N/A
- Revenue Growth
- CXAI N/A
- CRIS 14.17
- 52 Week Low
- CXAI $0.76
- CRIS $1.02
- 52 Week High
- CXAI $3.76
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- CXAI 51.50
- CRIS 41.14
- Support Level
- CXAI $0.95
- CRIS $1.50
- Resistance Level
- CXAI $1.07
- CRIS $1.90
- Average True Range (ATR)
- CXAI 0.06
- CRIS 0.20
- MACD
- CXAI 0.01
- CRIS -0.06
- Stochastic Oscillator
- CXAI 61.36
- CRIS 35.51
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.